Can the DIO2 rs225014 CC genotype cause tissue-specific T3 deficiency and persistent hypothyroid symptoms despite normal serum tests?

The DIO2 rs225014 polymorphism represents a critical genetic determinant of tissue-specific thyroid hormone bioactivity, frequently explaining why some individuals fail to achieve complete symptom resolution despite biochemically optimal serum thyroid levels.

Mechanistic pathways of local T3 deficiency

• Enzyme Dysfunction: The DIO2 rs225014 CC (Ala/Ala) genotype codes for a functionally hypomorphic type 2 deiodinase (D2) enzyme. This key selenoenzyme is responsible for converting thyroxine (T4) into biologically active triiodothyronine (T3) within target tissues such as the brain and skeletal muscle.
• Intracellular Misrouting: The Thr92Ala substitution does not fundamentally alter classical catalytic kinetics ($K_m$ or $V_{max}$). Instead, the Ala92-D2 variant undergoes aberrant trafficking, mislocalizing and accumulating in the trans-Golgi rather than cycling through normal endoplasmic reticulum (ER)-Golgi intermediate compartments.
• ER Stress Induction: This cellular accumulation triggers ER stress and activates the unfolded protein response. Combined with altered ubiquitination-mediated degradation, this proteostatic stress reduces the steady-state pool of active, functional D2, leading to localized intracellular T3 deficiency.

Clinical evidence and persistent symptoms

• Symptom Persistence: Because the resulting T3 deficiency is tissue-specific, individuals with the CC genotype often suffer from persistent hypothyroid symptoms—such as fatigue, depressive mood, and cognitive slowing—even when standard serum thyroid panels (TSH and free T4) are clinically normal.
• Serum Concordance and Treatment Preference: Clinical cohorts of thyroidectomized patients on standard levothyroxine (LT4) monotherapy carrying the CC genotype show lower serum T3/T4 ratios compared to Thr/Thr carriers. Consequently, patients with this genetic profile demonstrate significant symptomatic improvement and a strong clinical preference for T3/T4 combination replacement therapies over LT4 alone.

Bottom line

• The DIO2 rs225014 CC genotype impairs intracellular T4-to-T3 conversion by causing D2 protein mislocalization and ER stress. This results in localized tissue-specific hypothyroidism and persistent symptoms like fatigue and cognitive slowing despite normal routine serum thyroid tests, providing a biological rationale for T3/T4 combination therapy in symptomatic carriers.